Aripiprazole in mixed depressio
Phase 2
- Conditions
- Major Depressive Disorder.Depressive episode
- Registration Number
- IRCT201202122935N7
- Lead Sponsor
- Vice chancellor for research, Kurdistan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Presence of Major Depressive Disorder based on DSM-IV criteria; presence of mixed depression criteria (psychomotor or inner agitation).
Exclusion criteria: Presence of Psychosis; any diagnosis in Axis I and II; Receiving psychotropic medications; receiving any antidepressants during past one month or ECT during past two months; neurological disease; nursing and pregnant women; substance abuse during past two weeks
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of depression. Timepoint: Baseline and weeks 2-4-6-12 after beginnig of treatment. Method of measurement: by Hamiltion Depression Rating Scale 17-Item.
- Secondary Outcome Measures
Name Time Method Severity of anxiety. Timepoint: Baseline and weeks 2,4, 6 and 12 after starting treatment. Method of measurement: by Hamilton rating scale for anxiety.;Severity of agitation. Timepoint: Baseline and weeks 2,4, 6 and 12 after starting treatment. Method of measurement: by Young mania rating scale.